

**CAMSING HEALTHCARE LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration Number: 197903888Z)  
(the “**Company**”)

---

**RECEIPT OF APPROVAL IN-PRINCIPLE OF THE RESUMPTION OF TRADING PROPOSAL**

---

*The Company would like to remind all shareholders that trading in the Company’s shares is currently suspended. Shareholders and investors are advised to exercise caution when dealing in the Company’s shares and to refrain from taking any action in respect of their shares and/or investment in the Company which may be prejudicial to their interest. Persons, who are in doubt, as to the action they should take, should consult their stockbroker, bank manager, solicitor, accountant or other professional advisers.*

*Capitalised terms in this announcement (this “**Announcement**”) shall have the same meanings as ascribed to them in the Company’s announcement dated 14 June 2023, 15 June 2023, 6 February 2024 and 3 May 2024 (the “**Previous Announcement**”), unless otherwise defined.*

**1. RECEIPT OF APPROVAL IN-PRINCIPLE**

1.1. The Board of Directors (the “**Board**” or “**Directors**”) of Camsing Healthcare Limited (the “**Company**”) refers to the Previous Announcements and is pleased to announce that the Company, has on 10 May 2024, received a notification from SGX RegCo there are no further clarifications on the Resumption Proposal and that the SGX RegCo has approved in-principle the Resumption Proposal (the “**AIP**”)

1.2. The AIP is subject to the following:

(a) compliance with all the conditions stated under the letters issued by SGX RegCo dated 2 May 2024, with regard to circular to shareholders and the approval-in-principle for the listing and quotation of:

(i) up to 60,000,007 new ordinary shares in the capital of the company (the “**Subscription Shares**”) pursuant to the proposed Placement at an issue price of \$0.05 per share; and

(ii) up to 50,000,000 conversion shares to be issued pursuant to the proposed Issuance of unlisted zero-coupon mandatory convertible bonds in the principal amount of up to \$2,500,000 at the conversion price of \$0.05 per share upon conversion of such bonds (the “**Bonds**”);

(b) completion of the placement of all the Subscription Shares to the respective investors; and

(c) completion of the issuance of all the Bonds to the respective investors.

1.3. The AIP is not to be taken as an indication of the merits of the Resumption Proposal, the Bonds, the Conversion Shares, the Placement, the Subscription Shares, the Company and/or its subsidiaries.

- 1.4. The Company will make further announcements from time to time as may be necessary or appropriate in connection with the Resumption Proposal, including the fulfilment of the conditions.

## **2. CAUTIONARY STATEMENT**

- 2.1. Shareholders should note that the New Investment remain subject to several conditions precedent and the approval of the Independent Shareholders at the extraordinary general meeting of the Company which will be convened on 24 May 2024 to approve the Transaction Resolutions. There is no certainty or assurance that the conditions precedent can be fulfilled, or that the proposed transactions contemplated under the New Investment Agreements will be completed. Although the Company's shares are under suspension, shareholders and investors are advised to exercise caution when dealing in the Company's shares and to refrain from taking any action in respect of their shares and/or investment in the Company which may be prejudicial to their interest. Persons, who are in doubt, as to the action they should take, should consult their stockbroker, bank manager, solicitor, accountant or other professional advisers.

### **BY ORDER OF THE BOARD**

Yeo Choon Tat  
Executive Director  
10 May 2024